Medical team discussing integrated obesity care with GLP-1 drugs, endoscopy, surgery and precision medicine.
Medical team discussing integrated obesity care with GLP-1 drugs, endoscopy, surgery and precision medicine.
Bild generiert von KI

Updated POWER framework urges multidisciplinary obesity care beyond GLP-1 drugs

Bild generiert von KI
Fakten geprüft

A new Gastroenterology commentary revisits the American Gastroenterological Association’s 2017 POWER framework, arguing that GLP-1 medicines should be integrated with endoscopic therapies, bariatric surgery and precision medicine to improve long-term obesity outcomes.

Specialists have revisited the American Gastroenterological Association’s 2017 POWER (Practice Guide on Obesity and Weight Management, Education, and Resources) framework in light of the rise of GLP-1–based weight-loss medicines such as semaglutide and tirzepatide. The authors say the popularity of drugs including semaglutide (sold as Ozempic, Wegovy and Rybelsus) and tirzepatide (sold as Mounjaro and Zepbound) has reshaped obesity treatment, but they argue medication alone is not a complete solution.

Published as a commentary in the AGA journal Gastroenterology and titled “Revisiting POWER in the GLP-1 Age,” the update calls for a broader, multidisciplinary model that combines medications with minimally invasive endoscopic procedures and bariatric surgery when appropriate, while incorporating advances in precision medicine.

The authors point to growing evidence supporting endoscopic bariatric and metabolic therapies, including endoscopic sleeve gastroplasty, and they caution against relying on body mass index (BMI) alone to assess obesity-related health risk. The framework also incorporates the emerging concept of “clinical obesity,” describing obesity as a chronic disease that can affect multiple body systems.

The commentary underscores the role of gastroenterologists and hepatologists in obesity care, noting that they frequently treat conditions linked to obesity, including metabolic dysfunction-associated steatotic liver disease (MASLD), gastroesophageal reflux disease (GERD), gallbladder disease and other gastrointestinal complications.

Finally, the authors cite evidence suggesting that pairing GLP-1 medications with endoscopic procedures or bariatric surgery could produce greater weight loss and longer-lasting results than using any single approach alone.

Was die Leute sagen

Initial discussions on X are limited but include summaries from medical accounts highlighting the need for multidisciplinary obesity care integrating GLP-1 drugs with other therapies. Posts emphasize personalized approaches and the role of gastroenterologists. Reactions are mostly neutral and informative, with some direct links to the source article.

Verwandte Artikel

Realistic illustration contrasting social stigma: neutral for overweight, positive for exercise weight loss, negative for Ozempic users.
Bild generiert von KI

Study finds people who use Ozempic-like drugs for weight loss face added stigma

Von KI berichtet Bild generiert von KI Fakten geprüft

People who lose weight using GLP-1 medications such as Ozempic and Wegovy may be judged more negatively than those who lose weight through diet and exercise — and even more negatively than people who do not lose weight at all — according to a new study led by Rice University psychologist Erin Standen.

Scientists have developed a hybrid obesity treatment that uses GLP-1 and GIP signals to deliver a metabolic enhancer directly into cells. Early tests in mice showed greater weight loss and better blood sugar control than standard therapies. The approach aims to reduce side effects by limiting the drug's action to targeted areas.

Von KI berichtet

A large study tracking nearly 100,000 people in Sweden found that GLP-1 receptor agonists like semaglutide, sold as Ozempic and Wegovy, are associated with significantly fewer psychiatric hospital visits and reduced sick days due to mental health issues. Researchers observed drops of up to 47% in various mental health risks during drug use periods. The findings appear in The Lancet Psychiatry.

Adults with obesity who began taking GLP-1 receptor agonist medications showed declines in Fitbit-measured physical activity after starting treatment, according to a retrospective study presented Saturday at ENDO 2026, the Endocrine Society’s annual meeting in Chicago.

Von KI berichtet

The US Food and Drug Administration approved Foundayo, a new once-daily pill for obesity treatment, on Wednesday. Eli Lilly, the manufacturer, also produces the weight-loss injection Zepbound. The approval positions Foundayo as the second obesity pill cleared by the FDA.

Researchers at the University of Pennsylvania used artificial intelligence to analyze more than 400,000 Reddit posts about GLP-1 medications such as semaglutide and tirzepatide, identifying frequently discussed symptoms—including menstrual changes and temperature-related complaints—that may be less prominent in clinical trial reporting and drug labeling.

Von KI berichtet Fakten geprüft

University of Utah scientists report that a radical SAM enzyme known as PapB can join the ends of certain therapeutic peptides to form stable, ring-shaped structures. In experiments described in ACS Bio & Med Chem Au, the enzyme macrocyclized GLP-1-like peptides—including versions containing nonstandard amino acids found in some modern incretin drugs—an approach the researchers say could help make GLP-1 medicines such as semaglutide (Ozempic and Wegovy) more resistant to breakdown.

Diese Website verwendet Cookies

Wir verwenden Cookies für Analysen, um unsere Website zu verbessern. Lesen Sie unsere Datenschutzrichtlinie für weitere Informationen.
Ablehnen